May 17, 2022

Bayer to Rethink Roundup Formula for U.S. Consumers

Bayer AG said it will evaluate whether to continue using the active ingredient in its popular Roundup weedkiller in the residential U.S. market, in the wake of a court setback Wednesday in the company’s efforts to limit future liability over whether the product causes cancer.

Bayer has said it would pay up to $9.6 billion to settle existing Roundup cases that tie the glyphosate-based product to non-Hodgkin lymphoma and another $2 billion toward future claims. The German company lost three trials between 2018 and 2019 brought by Roundup users who said the product caused their cancer and is working to resolve around 125,000 similar claims.

The company’s attempt to resolve the future cases came in the form of a novel class-action settlement, which sought to bind people who have used Roundup but aren’t yet sick, as well as Roundup users with cancer who haven’t already sued.

In a six-page Wednesday order, U.S. District Judge

Vince Chhabria

in San Francisco concluded that the proposal would benefit the company much more than Roundup users who blame the product for causing cancer. He pointed to what he called “glaring flaws,” including that it offered few benefits for those who haven’t yet gotten sick while forcing them to give up substantial legal rights down the line.

Hours after the order, Bayer said it would abandon its efforts at a court-approved solution to address its future Roundup liability, which it said would have been the fairest, most-efficient approach.

Instead, the company said it will pursue several avenues, including creating a new website with studies relevant to Roundup’s safety that could also be reflected on its label. Bayer, which stands by the safety of Roundup and its main ingredient, glyphosate, said the website wouldn’t draw any safety conclusions but would help users make their own decisions.

The company also said it would rethink selling glyphosate-based products to the U.S. residential market but not to professional or agricultural users. The bulk of the lawsuits, it said, have come from U.S. residential consumers.

The company could continue selling products under the Roundup brand but without glyphosate.

Elizabeth Cabraser,

a plaintiffs’ lawyer who helped create the proposal, said she was disappointed by the ruling and still believes such a settlement would “provide tremendous financial, health and safety benefits for class members.”

Investors have been keenly awaiting Judge Chhabria’s decision, hoping an approval of the proposal would help break a yearslong downward spiral of the company’s share price, analysts say.

The challenge for Bayer is how to contain liability on a product that it continues to sell without any warning label. The U.S. Environmental Protection Agency has said the product is safe and wouldn’t permit a cancer warning.

At a daylong hearing earlier this month, attorneys pushing the proposal argued that it was intended to benefit migrant farmers and agricultural workers who use Roundup often but haven’t been a huge part of the plaintiff pool in the existing Roundup cases. During the hearing, Judge Chhabria called that reasoning a “straw man” that didn’t make up for its failings.

Bayer and plaintiffs’ lawyers had proposed creating a medical monitoring program to help Roundup users detect cancer early. Non-Hodgkin lymphoma, however, is difficult to detect before symptoms appear, which Judge Chhabria said made the benefits of such a program “far less meaningful than the attorneys suggest.” He also blasted a compensation fund that was only guaranteed to run for around four years, finding that the long latency period of NHL means most people who aren’t yet sick would be unlikely to benefit from it.

Judge Chhabria suggested at the hearing that the company craft a label that doesn’t concede the product causes cancer but explains the contrasting scientific findings of U.S. and international agencies, some of which have suggested a cancer link. Bayer has contended that the EPA would block any such a label.

The judge had said at the hearing he wouldn’t issue a ruling quickly, but noted in his written order that he changed his mind after concluding that “mere tweaks cannot salvage the agreement.” The proposal was Bayer’s second attempt at resolving future claims.

Bayer shareholders have been frustrated with the loss in market value and slow progress in resolving the protracted legal battle. The company inherited the Roundup cases with its 2018 acquisition of Monsanto for $63 billion, and the company’s share price is down more than 40% from pre-acquisition levels.

Negotiations with plaintiffs’ lawyers on settling pending lawsuits have also dragged on for months.

In its first-quarter report on May 7, Bayer said it had resolved roughly 96,000 claims out of a total of 125,000. Earlier this month, Bayer also lost an appeal in one of the three cases to go to trial. The company said Wednesday it will continue appeals in the existing cases and seek a decision by the U.S. Supreme Court.

Write to Sara Randazzo at [email protected] and Ruth Bender at [email protected]

Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Related Posts

Regeneron’s Covid-19 Drug Is Authorized for Injection

June 4, 2021

June 4, 2021

U.S. health regulators have authorized newer, more convenient forms of a Covid-19 antibody drug made by Regeneron Pharmaceuticals Inc. REGN...

EA, Other Videogame Companies Target Mobile Gaming as Pandemic Wanes

July 3, 2021

July 3, 2021

Videogame companies are increasing their financial bets on mobile games as pandemic restrictions ease and people ditch their PC and...

Biden, Senators Agree to Roughly $1 Trillion Infrastructure Plan

June 24, 2021

June 24, 2021

WASHINGTON—President Biden and a group of centrist senators agreed to a roughly $1 trillion infrastructure plan, securing a long-sought bipartisan...

Electric-Vehicle Spat Looms Over Biden’s Meeting With Canadian, Mexican Leaders

November 19, 2021

November 19, 2021

President Biden’s summit with counterparts from Canada and Mexico at the White House brought him face to face with leaders...

Exxon vs. Activists: Battle Over Future of Oil and Gas Reaches Showdown

May 25, 2021

May 25, 2021

For years, Exxon Mobil Corp. didn’t have to pay much attention to investors because of its gargantuan profits. Yet on...

G-7 Tax Plan: What We Know About the Global Corporate Tax Deal

June 8, 2021

June 8, 2021

Seven wealthy countries have announced a plan to impose a minimum levy on multinational corporations and rewrite the rules governing...

Walgreens Sales Rise as Vaccinations Improve Prescriptions Business

July 1, 2021

July 1, 2021

Sales and profit strengthened in the latest quarter for Walgreens Boots Alliance Inc., as the vaccination campaign that the company...

Tesla to Introduce Upgraded Model S to Jump-Start High-End Model Sales

June 10, 2021

June 10, 2021

Elon Musk is aiming to breathe new life into Tesla Inc.’s TSLA 1.49% high-end sedan that helped establish the company...

Toshiba Scandal Emboldens Foreign Investors Pushing Change in Japan

June 29, 2021

June 29, 2021

TOKYO—When Toshiba Corp.’s shareholders ousted the company’s chairman last week, it was a symbolic instance of foreign activist investors wielding...

Biden’s Capital-Gains Tax Proposal Puts Estate Planners to Work

June 8, 2021

June 8, 2021

Estate planners for the wealthiest Americans are combing through the Biden administration’s proposed tax increases, hunting for ways to sidestep...

Biden Expected to Propose $6 Trillion Budget

May 27, 2021

May 27, 2021

WASHINGTON—President Biden is expected to propose a $6 trillion budget on Friday that would lay the foundation for his plans...

Venmo to Charge Users for Selling Goods and Services

June 26, 2021

June 26, 2021

Venmo, the payments app owned by PayPal Holdings Inc., PYPL -1.23% will soon allow users to sell products and services...

Private-Equity Group Nears Deal to Buy Medline for Over $30 Billion

June 5, 2021

June 5, 2021

A group of private-equity firms is nearing a deal to acquire Medline Industries Inc. that would value the medical-supply giant...

Canadian Pacific Declines to Increase Offer for Kansas City Southern

May 20, 2021

May 20, 2021

Canadian Pacific Railway Ltd. said Thursday it won’t increase its takeover offer for Kansas City Southern , betting recent setbacks...

Millions of J&J Covid-19 Vaccines Are at Risk of Expiring in June

June 8, 2021

June 8, 2021

Hospitals, state health departments and the federal government are racing to decide how to use up millions of Johnson &...